Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 5Multiple Myeloma 4Hematologic Neoplasms 4Carcinoma, Renal Cell 4Breast Neoplasms 4Prostatic Neoplasms 3Neuroendocrine Tumors 3Urothelial Cancer 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Mantle-Cell 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Adenoma, Islet Cell 2von Hippel-Lindau Disease 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Thoracic Neoplasms 1Stomach Neoplasms 1

Interventions

trastuzumab deruxtecan 1taxane 1pertuzumab 1eribulin 1Trastuzumab 1Paclitaxel 1Carboplatin 1Capecitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Neoplasm Metastasis × 30 days × Clear all
NCT04784715 2026-05-22

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

AstraZeneca

Phase 3 Active not recruiting
1,157 enrolled 1 FDA
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT05374512 2026-05-15

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

AstraZeneca

Phase 3 Active not recruiting
644 enrolled 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡